News > Latest News

Walk News | Sponsor & Foundation News | News in the Parkinson's Disease Community

Adamas Announces U.S. Commercial Launch of GOCOVRI™ the First and Only FDA Approved Medication for the Treatment of Dyskinesia in Parkinson's Disease Patients

(January 11, 2018) - Adamas Pharmaceuticals, Inc. announced the full commercial launch of its flagship product, GOCOVRI™ (amantadine) extended release capsules, for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI was approved by the U.S. Food and Drug Administration (FDA) in August 2017, when it was granted seven years of orphan drug exclusivity, and has been available for physician and patient use since October 2017. Read more